Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Targeting Glutathione and Cystathionine β-Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation.

Santos I, Ramos C, Mendes C, Sequeira CO, Tomé CS, Fernandes DGH, Mota P, Pires RF, Urso D, Hipólito A, Antunes AMM, Vicente JB, Pereira SA, Bonifácio VDB, Nunes SC, Serpa J.

Nutrients. 2019 Oct 19;11(10). pii: E2523. doi: 10.3390/nu11102523.

2.

Unraveling FATP1, regulated by ER-β, as a targeted breast cancer innovative therapy.

Mendes C, Lopes-Coelho F, Ramos C, Martins F, Santos I, Rodrigues A, Silva F, André S, Serpa J.

Sci Rep. 2019 Oct 1;9(1):14107. doi: 10.1038/s41598-019-50531-3.

3.

Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity.

Nunes SC, Ramos C, Lopes-Coelho F, Sequeira CO, Silva F, Gouveia-Fernandes S, Rodrigues A, Guimarães A, Silveira M, Abreu S, Santo VE, Brito C, Félix A, Pereira SA, Serpa J.

Sci Rep. 2018 Jun 22;8(1):9513. doi: 10.1038/s41598-018-27753-y.

4.

Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer.

Nunes SC, Lopes-Coelho F, Gouveia-Fernandes S, Ramos C, Pereira SA, Serpa J.

BMC Evol Biol. 2018 Jun 19;18(1):97. doi: 10.1186/s12862-018-1214-1.

5.

Evaluation of percutaneous absorption performance for human female sexual steroids into pentravan cream.

Polonini HC, Brandão MA, Ferreira AO, Ramos C, Raposo NR.

Int J Pharm Compd. 2014 Jul-Aug;18(4):332-40.

PMID:
25474862

Supplemental Content

Loading ...
Support Center